辛伐他汀联合丹参酮治疗急性脑梗死的临床观察

Clinical Research on Simvastatin Combined with Tanshinone in the Treatment of Acute Cerebral Infarction

目的:探讨辛伐他汀联合丹参酮对急性脑梗死患者的治疗效果。方法:急性脑梗死患者随机分为观察组(n=50)与对照组(n=50)。对照组给予丹参酮治疗,观察组在对照组基础上加用辛伐他汀治疗,疗程均为14 d。治疗前后对两组患者的NIHSS(神经功能缺损程度)、ADL(日常生活活动量)及治疗疗效进行综合评价并比较。结果:与治疗前比较,两组患者NIHSS与ADL评分均明显改善,且观察组改善程度明显优于对照组(P<0.05);观察组治疗总有效率为90%,明显高于对照组的70%(P<0.05)。结论:辛伐他汀联合丹参酮治疗急性脑梗死疗效显著,且能明显改善患者神经缺损及日常生活活动量。

Objective： To analyze the effect of simvastatin combined with tanshinone in the treatment of patients with acute cerebral infarction. Methods： The patients with acute cerebral infarction were randomly divided into the treatment group （ n = 50） and the control group （n = 50）. The control group was given tanshinone treatment, the treatment group was given simvastatin treatment additionally, and the treatment course was 14 d. The NIHSS （nerve function defect degree）, ADL （daily life activity） and the treatment effect before and after the treatment were comprehensively evaluated and compared between the two groups. Results： Compared with those before the treatment, the NIHSS and ADL scores were significantly improved in the two groups after the treatment, and the differences were statistically significant （ P 〈 0.05）, and the improvement in the treatment group was significantly better than that in the control group with statistical significance （P 〈 0.05 ）. The total effective rate of the observation group was 98%, which was higher than that （70%） in the control group （P 〈 0.05 ）. Conclusion： Simvastatin combined with tanshinone in the treatment of acute cerebral infarction shows obvious therapeutic effect, which can obviously improve neurologic deficits and daily life activity, and is worthy of further clinical application.